“…In October 1999, a new class III antiarrhythmic drug, dofetilide, was approved for treatment of atrial fibrillation in the United States (Pfizer, 2011). Atrial fibrillation, the most common sustained cardiac arrhythmia, affects more than 6 million people in the United States (American Heart Association, 2015) and 33 million worldwide (Chugh, Havmoeller, Narayanan, Singh, Rienstra, Benjamin, Gillum, Kim, McAnulty, Zheng, Forouzanfar, Naghavi, Mensah, Ezzati, and Murray, 2014). Dofetilide cardioverts persistent atrial fibrillation to sinus rhythm by selectively blocking the rapid delayed rectifier potassium current, which slows the efflux of potassium ions, reduces the repolarization rate of the cell, and widens the plateau of the action potential (Mirams, Cui, Sher, Fink, Cooper, Heath, McMahon, Gavaghan, and Noble, 2011).…”